Tests a scan to guide adrenal surgery in primary aldosteronism
Tests a gallium-68 pentixafor PET scan in adults with primary aldosteronism.
Key facts
- Who runs it
- Seoul National University Hospital
- Where
- Seoul, South KoreaSee the 2 sites
- Trial code
- Registry title
- PETAL Trial: Impact of Gallium-68 Pentixafor PET-CT on Surgical Outcomes in Primary Aldosteronism
- Status
- Recruiting
- People taking part
- 90 people, planned
- Started
- 25 Jun 2025
- Expected to end
- 1 Dec 2027
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- 68Ga-pentixafor PET/CT
- Record updated
- 18 June 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with primary aldosteronism (too much of the hormone aldosterone) who had an adrenal CT scan. It tests whether an added PET/CT scan improves surgery results.
- Age
- 19 years or older
- Sex
- All sexes can join.
- Disease stage
- Primary aldosteronism diagnosed under the 2016 Endocrine Society guidelines.
- Earlier treatment
- An adrenal CT scan must have been done. People with earlier open abdominal surgery or retroperitoneal surgery on the same side as the planned adrenalectomy cannot join.
Main reasons for not taking part
- Pregnant or breastfeeding women, or women who may become pregnant
- People who refuse to have surgery
- People who cannot have, or refuse, the 68Ga-Pentixafor PET/CT, 11C-Metomidate PET/CT or adrenal venous sampling (AVS)
- People who refuse or react badly to the dexamethasone needed before the 11C-Metomidate PET/CT
- Earlier open abdominal or retroperitoneal surgery on the same side as the planned adrenalectomy
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Age ≥19 years
- Diagnosed with PA per 2016 Endocrine Society guidelines
- Underwent adrenal CT
- Signed informed consent
Who cannot take part
- Individuals who refuse to undergo surgery
- Individuals who refuse or experience adverse effects from dexamethasone premedication required for 11C-Metomidate PET/CT
- Individuals for whom 68Ga-Pentixafor PET/CT, 11C-Metomidate PET/CT, or adrenal venous sampling (AVS) is not feasible or is refused due to underlying conditions
- Individuals with a history of abdominal open surgery or retroperitoneal surgery on the same side as the planned adrenalectomy
- Women who are pregnant, breastfeeding, or may become pregnant
- Any individual deemed unsuitable for the study at the discretion of the investigator
Where in South Korea
- Samsung Medical CenterSeoul, South KoreaContact: You bin Lee, M.D, Ph.DTaking people
- Seoul National University HospitalSeoul, South KoreaContact: Seungho Lee, M.DTaking people
About the trial
What the trial wants to find out
This study is a randomized controlled trial to assess the clinical utility of gallium-68 pentixafor PET/CT in the management of primary aldosteronism (PA). We aim to evaluate whether the addition of 68Ga-pentixafor PET/CT to standard adrenal venous sampling (AVS) improves surgical outcomes in patients with unilateral PA.
The 2 groups in the trial
- AVS + 68Ga-pentixafor PET/CT (+ 11C-metomidate PET/CT)Treatment being tested
Intervention: Diagnostic Imaging: 68Ga-pentixafor PET/CT With 68Ga-pentixafor PET/CT imaging added to AVS for lateralization Subset only: 11C-metomidate PET/CT (for research use only, not used in treatment decisions)
Treatment: 68Ga-pentixafor PET/CT
- AVS onlyNo study treatment, for comparison
No PET/CT Without 68Ga-pentixafor PET/CT imaging; AVS only (Gold standard)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomized Controlled Trial to Evaluate the Effect of Gallium-68 Pentixafor PET-CT on Surgical Outcomes in Patients With Primary Aldosteronism (The PETAL Trial)
- Plain-language title
- Tests a scan to guide adrenal surgery in primary aldosteronismGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 18 June 2025